
About the Program
Program Overview
The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 27th Conference on Retroviruses and Opportunistic Infections (CROI 2020). This program consists of three components: (1) CME Internet Symposium: CROI 2020 Expert Review: an Internet symposium that features an overview of key presentations and posters, selected by the expert faculty discussants; and (2) Rapid-Fire Review of CROI 2020: a podcast that provides a brief, audio summary of the most essential data presented at the conference.
The CME Internet Symposium: CROI 2020 Expert Review will feature a panel of HIV experts reviewing and discussing key presentations on antiretroviral therapy presented at CROI 2020. The review and discussion will focus on HIV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations, therapies in development, epidemiology, and diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at www.viraled.com.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at CROI 2020 and it is not sanctioned by the organizers of CROI 2020.
Media: Internet
Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
Learning Objectives
After completing these activities, participants should be better able to:
- Apply in a clinical setting the most current HIV prevention and treatment approaches and paradigms
- Influence retention of patients on ARV therapy by addressing ARV side effects that can interfere with adherence to ARV regimens
- Employ the rapid initiation of appropriate and effective antiretroviral therapy
- Describe new antiretroviral agents in development and how they may be used in the treatment of people with HIV infection
Release Date: March 17, 2020
Expiration Date: March 17, 2021
Estimated time to complete the program: 15-45 minutes per module
Media: Internet
Back to Top
Faculty
José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain
Marta Boffito, MD, PhD
St. Stephen's AIDS Trust and Imperial College
Chelsea and Westminster Hospital
London, United Kingdom
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine
University Hospital
Bonn, Germany
Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois
Joint Accreditation Statement
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
|
Credit Designation:
Studies in Prevention Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Studies in Treatment-Naive Patients Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Studies in Treatment-Experienced Patients Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Studies in Hepatitis and HIV C-infections Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Studies in Pharmacology Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Adverse Events and Co-morbidities Module:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with
high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financialrelationships or
relationships to products or devices they or their spouse/life partner
have with commercial interests related to the content of these CME
activities:
Jose Arribas, MD
- Consulting Fees:Janssen, MSD,ViiV, Alexa, Teva
Marta Boffito, MD
- Consulting Fees: Gilead, BMS, ViiV
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): Gilead, Janssen, ViiV, BMS
- Contracted Research: Gilead, Janssen, ViiV, BMS
Ian Frank, MD
- Consulting Fees: Gilead, GSK
- Contracted Research: Johnson & Johnson
Graeme Moyle, MD
- Consulting Fees: Theratechnologies, Gilead, ViiV
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): Theratechnologies, Gilead, ViiV
- Contracted Research (institution only): Amgen, Merck, Gilead, ViiV
Jürgen Rockstroh, MD
- Consulting Fees: Gilead, Merck, Janssen, Theratechnologies, ViiV
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents (eg. speakers' bureaus): AGilead, Merck, Janssen, ViiV
Paul Sax, MD
- Consulting Fees: Gilead, GSK/ViiV, Janssen, Merck
- Contracted Research: Gilead, GSK/ViiV, Merck
- Other (Editorial Boards): Medscape, UpToDate, NEJM Journal Watch, Open Forum ID
The PIM planners and managers have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and received CME credit for this activity. During the period, March 17, 2020 through March 17, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If
you wish to received acknowledgment of completing this activity, please
complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 15178. Upon
registering and successfully completing the activity evaluation, your certificate will be made
available immediately. Processing credit requests online will reduce
the amount of paper used by nearly 100,000 sheets per year.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications.
The opinions expressed in the educational activity are those of the
faculty and donot necessarily represent the views of the planners.
Please refer to the official prescribing information for each product for
discussion of approved indications, contraindications, and warnings.
Disclamer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Computer System Requirements
This
program requires a modern web browser (Internet Explorer 7+, Mozilla
Firefox, Apple Safari, Google Chrome). Certain educational activities
may require additional software to view multimedia, presentation, or
printable version of their content. These activities will be marked as
such and will provide links to the required software. That software may
be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint,
Windows Media Player and Real Networks Real One Player.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
|